Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;67(7):2899-2911.
doi: 10.1007/s10620-021-07131-x. Epub 2021 Jul 14.

Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats

Affiliations

Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats

Takako Nakashima et al. Dig Dis Sci. 2022 Jul.

Abstract

Background: Since gut microbiota is involved in the pathogenesis of inflammatory bowel disease (IBD), antibiotics or probiotics may be attractive options for the treatment of IBD. Akkermansia muciniphila is expected as a next-generation probiotic for IBD, and OPS-2071 is a novel quinolone with potent antibacterial activity against Clostridioides difficile.

Aims: The aim of this study is to assess the potential of OPS-2071 as a gut microbiota modulator for IBD.

Methods: Minimum inhibitory concentrations of several bacteria in the human intestinal microbiota were determined. Microbiota changes in the feces were typed using metagenomic analysis after oral administration of OPS-2071 (100 mg/kg) twice a day to normal rats. The amounts of mucin were determined using the Fecal Mucin Assay Kit. The effects of OPS-2071 (1, 3, 10 mg/kg) twice a day on fecal symptoms and fecal microbiota were evaluated in a colitis rat model induced by free access to drinking water containing 3% dextran sulfate sodium for 10 days.

Results: OPS-2071 showed notably low antibacterial activity against only A. muciniphila in spite of higher antimicrobial activity against other strains of intestinal bacteria. OPS-2071 rapidly and dramatically increased the occupancy of A. muciniphila as well as the amount of mucin in the feces of normal rats. OPS-2071 (10 mg/kg) significantly suppressed the exacerbation of stool scores, especially the bloody stool score, with the increase in A. muciniphila occupancy.

Conclusions: OPS-2071 is expected to be a new therapeutic option for IBD as a gut microbiota modulator by significantly increasing A. muciniphila occupancy.

Keywords: Akkermansia; Dextran sulfate sodium induced colitis; Gut microbiota; Inflammatory bowel disease; OPS-2071; Ulcerative colitis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kobayashi T, Siegmund B, Le Berre C et al. Ulcerative colitis. Nat Rev Dis Primers 2020;6:74. - DOI
    1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521–533. - DOI
    1. Guan QA. Comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019;2019:7247238. - DOI
    1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590–1605. - DOI
    1. Ma C, Battat R, Dulai PS et al. Innovations in oral therapies for inflammatory bowel disease. Drugs 2019;79:1321–1335. - DOI

Publication types

Supplementary concepts

LinkOut - more resources